Drug intelligence / Profile preview

Neo-Islets

Development stage: Unknown
Lead developer: SymbioCellTech
Modality: Cell Therapies
Administration: Intraperitoneal

Overview

Neo-Islets are investigational three-dimensional multicellular organoids developed by SymbioCellTech for diabetes. They are produced by co-culturing culture-expanded pancreatic islet cells with healthy mesenchymal stromal cells in an approximately 1:1 ratio. The islet-cell component is intended to restore glucose-responsive insulin production, while the mesenchymal stromal-cell component is intended to provide trophic, pro-angiogenic, anti-inflammatory, anti-fibrotic, and autoimmune and allogeneic immune-modulatory support that may improve islet survival and engraftment without systemic anti-rejection therapy. SymbioCellTech lists human Neo-Islets as SCT-h001 for type 1 and type 2 diabetes and canine Neo-Islets as SCT-c001 for canine diabetes.

Other names: NIsNeo-islets

Beyond the preview

Go deeper on Neo-Islets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neo-Islets.

Explore the full profile